@faanzy777: #vanzxy404 Dancing jodi😁🗿 cr/ib style:@2yuren_ #fyp #presetalightmotion #clanuzumaki #fyppppppppppppppppppppppp

校 - Vanzxy Uzumaki`𝐍𝐂𝐀᭄

Open In TikTok:

Region: ID

Wednesday 16 September 2026 15:31:14 GMT

87196

7362

103

558

Music

Download

No Watermark .mp4 (3.85MB) No Watermark(HD) .mp4 (3MB) Watermark .mp4 (7.72MB) Music .mp3

Comments

Hamz🤯 :

kelamaan keburu di angkat saber bg

2026-09-16 19:16:06

41

校 - Vanzxy Uzumaki`𝐍𝐂𝐀᭄ :

Preset disini🗿👇🏻 Preset 5mb 2ukuran: https://alightcreative.com/am/share/u/moUgBD2AdLaj6ltOUlsUMeO6rQl1/p/Ec11G6fT1h-5aab7c557b213267 ===== Xml 2 ukuran (langsung gabungin): https://drive.google.com/file/d/1gLq6pLYtWJyI6pbrhcgMrg6ywJ8s9_Ke/view?usp=drivesdk ===== Note:boleh pake, asalkan jangan ngaku/claim kalo ini preset lu😑🗿

2026-09-16 19:40:47

24

Diky Nvbrz05 :

font nike name dmn?

2026-09-20 16:16:59

2

broccoli itu sehat :

simpan dulu lah, nnti tunggu tinggi gua udh 180cm baru pake, sekarang masih 173cm, jdi malu padahal umur dah 16thn 😭

2026-09-19 10:15:47

3

🗿 :

dulu aku ceria 😁, sekarang aku kejam 👿

2026-09-17 09:39:12

6

Sen :

development

2026-09-16 22:20:17

1

𝐉𝐔𝐍 `𝘼𝙎𝘾᭄ :

harusnya top my bini 🗿

2026-09-16 22:09:00

2

Hamzz-XmL :

wm narutonya bagi

2026-09-18 11:46:28

3

–𝑲ynzzz :

preset bg

2026-09-17 10:33:14

1

𝓜𝓲𝓵𝓵 :

apa nama lagu ini bro

2026-09-17 15:06:55

3

𒆜𝐙𝐀𝐈𝐈𝐃𝐊 :

biar ga kepeleset adakah preset?🗿

2026-09-19 03:36:48

2

supreme king :

2026-09-17 01:36:42

1

ちわ^ Xzayn :

keburu di angkat Atlas ini mah😭

2026-09-19 10:54:50

2

𝙍𝙞𝙇 𝙆𝙞𝙩𝙖𝙜𝙖𝙬𝙖ᥫ᭡ :

Reirin bini guweh

2026-09-17 07:49:48

1

和凛 Warin :

nyimpen in preset tapi kaga pernah di pake🗿

2026-09-17 11:41:14

4

Rexyyy2 :

buat cinematik mantap ini🗿

2026-09-17 11:31:22

1

Dyeen :

preset woi

2026-09-16 18:01:32

1

— Ren Suka Bobo🪽 :

tiris kie laguna min

2026-09-18 12:52:53

1

• ROSYID :

ke 1.000 🤭😁

2026-09-16 23:32:31

1

𝗔𝗦𝗦 `Kylee. :

presett

2026-09-16 18:14:47

1

𝒀𝒖𝒔𝒖𝒑' :

https://alightcreative.com/am/share/u/moUgBD2AdLaj6ltOUlsUMeO6rQl1/p/Ec11G6fT1h-5aab7c557b213267

2026-09-17 05:27:49

1

705 Fanz ft GG :

guaa tau konsep nya gimana 🗿hahahha

2026-09-17 07:44:48

2

🎀🍹🌷🥀🌼 :

malah ngeramal finansial freedom Wak☠️

2026-09-17 05:24:34

1

lyzen :

iya mau presat😅

2026-09-16 17:19:27

1

putrazi23 :

2026-09-16 23:53:59

1

To see more videos from user @faanzy777, please go to the Tikwm homepage.

Other Videos

СашаТаня часть 7 #сашатаня #бубавпн

СашаТаня часть 7 #сашатаня #бубавпн

#☜♡☞ #الشـᬽـ꙰🖤ـامي🦅 #متابعة_قلب_تعليق_مشاركة_

#☜♡☞ #الشـᬽـ꙰🖤ـامي🦅 #متابعة_قلب_تعليق_مشاركة_

кель’тас #edit #rypシ #warcraft3 #слайдшоу

кель’тас #edit #rypシ #warcraft3 #слайдшоу

Headline Hype vs. Clinical Reality When headlines use words like “terrifying” around GLP-1s, it’s normal to feel concerned. Looking past clickbait to understand real-world clinical math helps you make confident, empowered health decisions. 1. Relative vs. Absolute Risk News outlets love relative risk because big multipliers drive clicks. Relative Risk: If a rare condition goes from 1 in 10,000 to 2 in 10,000, headlines scream

Headline Hype vs. Clinical Reality When headlines use words like “terrifying” around GLP-1s, it’s normal to feel concerned. Looking past clickbait to understand real-world clinical math helps you make confident, empowered health decisions. 1. Relative vs. Absolute Risk News outlets love relative risk because big multipliers drive clicks. Relative Risk: If a rare condition goes from 1 in 10,000 to 2 in 10,000, headlines scream "100% RISK INCREASE!" Absolute Risk: Your real-world chance only changed by 0.01% (from 0.01% to 0.02%). 2. The Vision Loss Risk (NAION) The Math: Multi-year registry data shows the cumulative absolute risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) for GLP-1 users remains low, at 3 to 4 cases per 10,000 people (<0.04%). Clinical Consensus: The AAO and NANOS joint consensus confirms that while a modest relative association exists (~2-fold), direct causality is unproven. ****Always monitor for visual changes and consult your provider. 3. The Unsung Benefit: Cancer Reduction Scary headlines ignore major positive clinical data (JAMA Oncology, JAMA Network Open). GLP-1s lower obesity-associated cancer risks across both relative and absolute metrics: Overall Cancer: An absolute drop of 2.8 fewer cases/1,000 people/year (drops from 16.4 to 13.6 per 1,000 person-years — a 17% relative reduction). Endometrial Cancer: An absolute drop of ~0.4 fewer cases/1,000 person-years (a 25% relative reduction). Ovarian Cancer: An absolute drop of ~0.2 fewer cases/1,000 person-years (a 47% relative reduction). Colorectal Cancer: An absolute drop of ~0.5–1 fewer cases/1,000 person-years (up to a 28% relative reduction). By improving metabolic health, lowering fasting insulin, and calming systemic inflammation, GLP-1s address root drivers of cellular damage. Educational Only. Not Medical Advice. It is still important to monitor for any visual changes, research any medication or supplement you take, and discuss any concerns directly with your provider. Silence Medical PLLC | Evidence-based metabolic care focused on muscle preservation. 📲 Telemedicine in AZ, CO, & OR | www.silencemed.com References Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024;142(8):731–739. doi:10.1001/jamaophthalmol.2024.2296 Grauslund J, et al. Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy. Acta Ophthalmol. Published online 2024. PMID: 39696569. DeParis S, Oke I, Gaier E, et al. Glucagon-like peptide-1 receptor agonists and the risk of non-arteritic anterior ischemic optic neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology. Ophthalmology. Published online August 2026. Biousse V. Consensus Statement Shows a Possible Small Association Between GLP-1 RA Drugs and NAION. American Academy of Ophthalmology (AAO) Editor's Choice. Published August 27, 2026. Dai H, Li Y, Lee Y, et al. GLP-1 receptor agonists and cancer risk in adults with obesity. JAMA Oncol. 2025;11(10):e252681. doi:10.1001/jamaoncol.2025.2681 Wang L, Xu R, Kaelber DC, Berger NA. GLP-1 Receptor Agonists and Risk of Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024;7(7):e2421305. doi:10.1001/jamanetworkopen.2024.21305 #GLP1 #WeightLossJourney #Telehealth #SilenceMedical #Semaglutide

Back to TikTok amigos ✌🏾😁 #football #deportesentiktok

Back to TikTok amigos ✌🏾😁 #football #deportesentiktok

About

Robot
API

Legal

Privacy Policy